Frontage Holdings Announces Proposed Privatization and Asset Restructuring Plan
Frontage Holdings Corporation (HKEX: 1521) has announced a proposal for privatization from the Hong Kong Stock Exchange, followed by a strategic asset restructuring. An investor consortium consisting of Charles River Laboratories, Tigermed, and Frontage Chairman Dr. Song Li will divide the company's business units to enhance operational agility. Under the proposed plan, Charles River Laboratories would acquire the bioanalysis and DMPK business based in Exton, Pennsylvania. Tigermed is expected to take ownership of the China-based operations and Acme Bioscience assets, while Dr. Song Li will manage the remaining international business outside of the PRC and Exton. The move aims to allow management to redeploy resources more effectively into core operations.

Tickers: $CRL
Topics: asset restructuring biotechnology corporate reorganization privatization